|MDACC Study No:||2012-1007 (clinicaltrials.gov NCT No: NCT01722487)|
|Title:||A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 versus Chlorambucil in Patients 65 Years or Older with Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|
|Principal Investigator:||Jan A. Burger|
|Treatment Agent:||Chlorambucil; PCI-32765|
|Study Description:||The goal of this clinical research study is to compare the level of |
effectiveness of PCI-32765 (ibrutinib) to that of chlorambucil when given to
patients with CLL or SLL. The safety of these drugs will also be compared.
Ibrutinib is designed to stop a protein from working in the cells, which may
cause the cancer cells to die or stop growing.
Chlorambucil is designed to lower the body's harmful response to immune system
diseases, which may cause cancer cells to die.